<\/p>\n
Atrest<\/strong> er en oral tetrabenazine<\/strong> (12.5 mg) tablet \u2014 a VMAT2 (vesicular monoamine transporter 2) inhibitor<\/strong> specifically approved for the treatment of chorea associated with Huntington disease<\/strong>. It works by depleting dopamine from nerve terminals, reducing the involuntary writhing and jerking movements that characterise Huntington chorea. Starting dose: 12,5 mg en gang dagligt<\/strong>, increased weekly by 12.5 mg to a maximum of 37.5 mg\/dose (75–100 mg\/day)<\/strong>, always divided into 2–3 doses. Patients receiving >50 mg\/day require CYP2D6 genotyping<\/strong>. Common side effects: sedation, akathisia, depression, parkinsonism, insomnia. Black-box warning:<\/strong> increases risk of depression and suicidality in Huntington patients \u2014 monitor mood closely.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n Atrest is an oral tablet containing tetrabenazine 12.5 mg<\/strong>. Tetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor<\/strong> — the first drug specifically approved for the treatment of chorea associated with Huntington disease<\/strong>.<\/p>\n By depleting presynaptic dopamine stores, tetrabenazine reduces the involuntary, dance-like movements (chorea) that characterise Huntington disease without the tardive dyskinesia risk of traditional dopamine receptor blockers. It was first used in Europe in the 1970s and gained FDA approval in 2008 as Xenazine<\/strong>. Atrest is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n Tetrabenazine irreversibly inhibits VMAT2<\/strong>, the protein responsible for packaging dopamine, serotonin, and norepinephrine into synaptic vesicles. By blocking VMAT2, the drug depletes presynaptic monoamine stores \u2014 predominantly dopamine in the basal ganglia. Excessive dopaminergic activity in the striatum is the primary driver of choreiform movements in Huntington disease, so reducing dopamine availability at the post-synaptic receptor directly suppresses chorea.<\/p>\n The drug is extensively metabolised by CYP2D6 into two active metabolites (α-HTBZ and β-HTBZ) that account for most of the clinical effect. CYP2D6 poor metabolisers<\/strong> have significantly higher plasma levels, which is why genotyping is required before exceeding 50 mg\/day.<\/p>\nHvorfor bestille fra MedsBase<\/h3>\n
What Is Atrest?<\/h2>\n
How Does Atrest (Tetrabenazine) Work?<\/h2>\n
Dosering og administration<\/h2>\n